Abstract
Alloantigen expression on host antigen-presenting cells (APCs) is essential to initiate graft-versus-host disease (GvHD); therefore, alloantigen expression on host target epithelium is also thought to be essential for tissue damage. We tested this hypothesis in mouse models of GvHD using bone-marrow chimeras in which either major histocompatibility complex class I or class II alloantigen was expressed only on APCs. We found that acute GvHD does not require alloantigen expression on host target epithelium and that neutralization of tumor necrosis factor-α and interleukin-1 prevents acute GvHD. These results pertain particularly to CD4-mediated GvHD but also apply, at least in part, to CD8-mediated GvHD. These results challenge current paradigms about the antigen specificity of GvHD effector mechanisms and confirm the central roles of both host APCs and inflammatory cytokines in acute GvHD.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Shlomchik, W.D. et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 285, 412–415 (1999).
Ferrara, J.L.M. & Deeg, H.J. Graft versus host disease. N. Engl. J. Med. 324, 667–674 (1991).
Crawford, J.M. Graft-versus-host disease of the liver. in Graft-versus-Host Disease (eds. Ferrara, J.L.M., Deeg, H.J. & Burakoff, S.J.) 315–336 (Marcel Dekker, New York, 1997).
Baker, M.B., Altman, N.H., Podack, E.R. & Levy, R.B. The role of cell-mediated cytotoxicity in acute GvHD after MHC matched allogeneic bone marrow transplantation in mice. J. Exp. Med. 183, 2645–2656 (1996).
Braun, Y.M., Lowin, B., French, L., Acha-Orbea, H. & Tschopp, J. Cytotoxic T cells deficient in both functional Fas ligand and perforin show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease. J. Exp. Med. 183, 657–661 (1996).
Korngold, R. & Sprent, J. T-cell subsets in graft-vs. -host disease. in Graft-vs.-Host Disease: Immunology, Pathophysiology, and Treatment (eds. Burakoff, S.J., Deeg, H.J., Ferrara, J. & Atkinson, K.) 31–50 (Marcel Dekker, New York, 1990).
Lampert, I.A., Suitters, A.J. & Chisholm, P.M. Expression of Ia antigen on epidermal keratinocytes in graft-versus-host disease. Nature 293, 149–150 (1981).
Mason, D.W., Dallman, M. & Barclay, A.N. Graft-versus-host disease induces expression of Ia antigen in rat epidermal cells and gut epithelium. Nature 293, 150–151 (1981).
Barclay, A.N. & Mason, D.W. Induction of Ia antigen in rat epidermal cells and gut epithelium by immunological stimuli. J. Exp. Med. 156, 1665–1676 (1982).
Surh, C.D. & Sprent, J. Homeostatic T cell proliferation. How far can T cells be activated to self-ligands? J. Exp. Med. 192, F9–F14 (2000).
Krasinskas, A.M. et al. Replacement of graft-resident donor-type antigen presenting cells alters the tempo and pathogenesis of murine cardiac allograft rejection. Transplantation 70, 514–521 (2000).
Paris, F. et al. Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science 293, 293–297 (2001).
Sitkovsky, M.V. & Henkart, P.A. Mechanisms of T-cell-mediated cytotoxicity in vivo and in vitro. in Graft-versus-Host Disease (eds. Ferrara, J.L.M., Deeg, H.J. & Burakoff, S.J.) 219–233 (Marcel Dekker, Inc., New York, 1997).
Hill, G.R. et al. Total body irradiation and acute graft versus host disease. The role of gastrointestinal damage and inflammatory cytokines. Blood 90, 3204–3213 (1997).
Hattori, K. et al. Differential effects of anti-Fas ligand and anti-tumor necrosis factor-α antibodies on acute graft-versus-host disease pathologies. Blood 91, 4051–4055 (1998).
Hill, G.R. et al. Differential roles of IL-1 and TNF-α on graft-versus-host disease and graft versus leukemia. J Clin Invest 104, 459–467 (1999).
Sprent, J., Schaefer, M., Gao, E.K. & Korngold, R. Role of T-cell subsets in lethal graft-versus-host disease (GvHD) directed to class I versus class II H-2 differences. I. L3T4+ cells can either augment or retard GvHD elicited by Lyt-2+ cells in class I different hosts. J. Exp. Med. 167, 556–569 (1988).
Amrani, A., Verdaguer, J., Thiessen, S., Bou, S. & Santamaria, P. IL-1α, IL-1β, and IFN-γ mark β cells for Fas-dependent destruction by diabetogenic CD4(+) T lymphocytes. J. Clin. Invest. 105, 459–468 (2000).
Nestel, F.P., Price, K.S., Seemayer, T.A. & Lapp, W.S. Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor α during graft-versus-host disease. J. Exp. Med. 175, 405–413 (1992).
Graubert, T.A., DiPersio, J.F., Russell, J.H. & Ley, T.J. Perforin/granzyme-dependent and independent mechanisms are both important for the development of graft-versus-host disease after murine bone marrow transplantation. J. Clin. Invest. 100, 904–911 (1997).
Blazar, B.R., Taylor, P.A. & Vallera, D.A. CD4+ and CD8+ T cells each can utilize a perforin-dependent pathway to mediate lethal graft-versus-host disease in major histocompatibility complex-disparate recipients. Transplantation 64, 571–576 (1997).
Mori, T. et al. Involvement of Fas-mediated apoptosis in the hematopoietic progenitor cells of graft-versus-host reaction-associated myelosuppression. Blood 92, 101–107 (1998).
Martin, P.J., Akatsuka, Y., Hahne, M. & Sale, G. Involvement of donor T-cell cytotoxic effector mechanisms in preventing allogeneic marrow graft rejection. Blood 92, 2177–2181 (1998).
Jiang, Z., Podack, E. & Levy, R.B. Major histocompatibility complex-mismatched allogeneic bone marrow transplantation using perforin and/or Fas ligand double-defective CD4(+) donor T cells: Involvement of cytotoxic function by donor lymphocytes prior to graft-versus-host disease pathogenesis. Blood 98, 390–397 (2001).
Santamaria, P. Effector lymphocytes in autoimmunity. Curr. Opin. Immunol. 13, 663–639 (2001).
Via, C.S., Nguyen, P., Shustov, A., Drappa, J. & Elkon, K.B. A major role for the Fas pathway in acute graft-versus-host disease. J. Immunol. 157, 5387–5393 (1996).
Piguet, P.F., Grau, G.E., Allet, B. & Vassalli, P.J. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-versus-host disease. J. Exp. Med. 166, 1280–1289 (1987).
Moser, B. & Loetscher, P. Lymphocyte traffic control by chemokines. Nature Immunol. 2, 123–128 (2001).
Murai, M. et al. Active participation of CCR5(+)CD8(+) T lymphocytes in the pathogenesis of liver injury in graft-versus-host disease. J. Clin. Invest. 104, 49–57 (1999).
Sallusto, F. et al. Distinct patterns and kinetics of chemokine production regulate dendritic cell function. Eur. J. Immunol. 29, 1617–1625 (1999).
Truitt, R.L., Johnson, B.D., McCabe, C. & Weiler, M.B. Graft versus leukemia. in Graft-versus-Host Disease (eds. Ferrara, J.L.M., Deeg, H.J. & Burakoff, S.J.) 385 (Marcel Dekker, Inc., New York, 1997).
Grusby, M.J., Johnson, R.S., Papaioannou, V.E. & Glimcher, L.H. Depletion of CD4+ T cells in major histocompatibility complex class II-deficient mice. Science 253, 1417–1420 (1991).
Wall, D.A. et al. Immunodeficiency in graft-versus-host reaction. I. Mechanism of immune suppression. J. Immunol. 140, 2970–2976 (1988).
Reddy, P. et al. Interleukin-18 regulates acute graft-versus-host disease by enhancing Fas-mediated donor T cell apoptosis. J. Exp. Med. 194, 1433–1440 (2001).
Cooke, K.R. et al. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation. I. The roles of minor H antigens and endotoxin. Blood 88, 3230–3239 (1996).
Cooke, K.R. et al. Host reactive donor T cells are associated with lung injury after experimental allogeneic bone marrow transplantation. Blood 92, 2571–2580 (1998).
Hill, G.R. et al. Interleukin-11 promotes T-cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation. J. Clin. Invest. 102, 115–123 (1998).
Teshima, T. et al. Tumor cell vaccine elicits potent antitumor immunity after allogeneic T-cell-depleted bone marrow transplantation. Cancer Res. 61, 162–171 (2001).
Acknowledgements
This work was supported by NIH grants CA39542 (to J.L.M.F.) and HL03565-05 (to K.C.).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Teshima, T., Ordemann, R., Reddy, P. et al. Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat Med 8, 575–581 (2002). https://doi.org/10.1038/nm0602-575
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/nm0602-575
This article is cited by
-
Allogeneic hematopoietic stem cell transplantation from a 2-HLA-haplotype-mismatched family donor for posttransplant relapse: a prospective phase I/II study
Bone Marrow Transplantation (2021)
-
Utility of novel T-cell-specific extracellular vesicles in monitoring and evaluation of acute GVHD
International Journal of Hematology (2021)
-
Short-term KRP203 and posttransplant cyclophosphamide for graft-versus-host disease prophylaxis
Bone Marrow Transplantation (2020)
-
Comparison of hemorrhagic and ischemic stroke after allogeneic hematopoietic stem cell transplantation
Bone Marrow Transplantation (2020)
-
Associations between febrile neutropenia-related parameters and the risk of acute GVHD or non-relapse mortality after allogeneic hematopoietic stem cell transplantation
Bone Marrow Transplantation (2019)